

Last updated:

February 5<sup>th</sup>, 2020



# Immune Tolerance Network: Trial Status

# Timeline Legend

**Yellow - Development:** Starts with protocol writing and other tasks including site selection, contracting and preparation and submission of an IND.

**Green - Enrollment:** Starts with the activation of the first site and continue until the last participant has first visit (LPFV).

**Blue - Follow up:** all trial activity starting with LPFV and concludes with last participant, last visit (LPLV).

**Red – Analysis:** Starts when all visits have been complete and includes data clean-up, database lock and reporting of clinical results.


# Allergy Trials - Development

## DEVELOPMENT


### ITN076AD FEAST Pilot : Food Exposure Allergy Suppression. Phase II



### ITN084AD GRADUATE: Subcutaneous grass pollen allergen immunotherapy. Phase II



### ITN087AD EFFECT: EFFicacy of Etokimab in Peanut Allergy, a Randomized Controlled Trial. Phase II




# Allergy Trials – Enrollment / Analysis

## ENROLLMENT

ITN070AD LEAP Trio: LEAP Participants and their families.

Observational

[ClinicalTrials.gov](https://clinicaltrials.gov)



ITN079AD ACTIVATE: Exposure to Vaginal Microbiome in C-section Infants

Phase II

[ClinicalTrials.gov](https://clinicaltrials.gov)




## ANALYSIS

ITN050AD IMPACT: Peanut Oral Immunotherapy in Children


Phase II

[ClinicalTrials.gov](https://clinicaltrials.gov)



ITN57AD CATNIP: Anti-TSLP Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy


Phase II [ClinicalTrials.gov](https://clinicaltrials.gov)



# Autoimmune Trials - Development

## DEVELOPMENT

### ITN086AI REVEAL: Evaluation of AMG 714 for Vitiligo. Phase II



### ITN091AI CD40L Antagonism in LN. VIB4920 vs. Placebo in Active Lupus Nephritis Phase II



### ITN092AI VIB4920 vs. Placebo in Rheumatoid Arthritis. Phase II




# Autoimmune Trials – Enrollment

## ENROLLMENT


ITN075AI BRAVOS: Brentuximab vedotin in diffuse cutaneous systemic sclerosis Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)



ITN077AI BEAT-MS: Best Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant for MS. Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)



ITN080AI REBOOT: Belimumab and Rituximab for Primary Membranous Nephropathy Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)




# Autoimmune Trial – Follow-Up / Analysis

## ANALYSIS


ITN055AI CALIBRATE: Rituximab and Belimumab for Lupus Nephritis

Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)



ITN059AI PAUSE: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris Phase II


[Clinicaltrials.gov](https://clinicaltrials.gov)



# Transplantation Trials - Development

## DEVELOPMENT

### ITN089ST: ADAPT Carfilzomib and Belatacept for Desensitization



### ITN090ST: ATTAIN Desensitization Study






# Transplantation Trials – Enrollment

## ENROLLMENT

ITN062ST TEACH: Tolerance by engaging antigen during cellular homeostasis Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)




ITN063ST ALLTOL: ALLograft TOLerance Study

Observational [Clinicaltrials.gov](https://clinicaltrials.gov)




ITN073ST LITTMUS MGH : Liver Transplantation with Tregs at MGH Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)



# Transplantation Trials– Follow Up

## FOLLOW UP


ITN056ST OPTIMAL: Senescence and Exhaustion Biomarkers of Operational Tolerance Following IS Withdrawal in Liver Transplant Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)



# Type 1 Diabetes Trials – Enrollment / Follow Up

## ENROLLMENT

ITN066AI T1DES: Long-Term Investigative Follow-up on Type 1 Diabetes Observational [Clinicaltrials.gov](https://clinicaltrials.gov)



## FOLLOW UP

ITN058AI EXTEND: Preserving Beta Cell Function with Tocilizumab in New Onset Type 1 Diabetes Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)




# ONGOING MECHANISTIC STUDY SUPPORT

## Type 1 Diabetes

ITN827AI TILT: T1DM Immunotherapy Using Polyclonal Tregs + IL-2 [Clinicaltrials.gov](https://clinicaltrials.gov)

ITN829AI INTREXON : ActoBio AG019 (L. lactis) and teplizumab

[Clinicaltrials.gov](https://clinicaltrials.gov)



## Transplantation

ITN803ST deLTa: darTregs in Liver Transplantation

[Clinicaltrials.gov](https://clinicaltrials.gov)

ITN823ST IWITH Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

[Clinicaltrials.gov](https://clinicaltrials.gov)

## Autoimmune

ITN803ST CAB-101 DSG3-CAART for anti-DSG3 pemphigus vulgaris

